ASH Clinical Practice Guidelines
ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are explicit about how recommendations were determined and open about the quality of evidence that factored into the final decision-making process.
Browse the existing guidelines below, and learn about guidelines currently in development, including those open for public comment.
Ten ASH Clinical Practice Guidelines on Venous Thromboembolism covering prophylaxis for medical patients, diagnosis, anticoagulation therapy, heparin-induced thrombocytopenia, pregnancy, pediatrics, treatment, cancer, thrombophilia, prophylaxis in surgical patients, and anticoagulation in COVID-19 patients.
Five ASH Sickle Cell Disease Guidelines covering cardiopulmonary and kidney disease, cerebrovascular disease, transfusion, transplantation, and pain management.
An update to the 2011 ASH Clinical Practice Guidelines for Immune Thrombocytopenia covering management of both adult and pediatric immune thrombocytopenia.
The ASH Clinical Practice Guidelines for Acute Myeloid Leukemia covers the treatment of acute myeloid leukemia in older adults.
Two ASH Clinical Practice Guidelines will cover the treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
Two ASH Clinical Practice Guidelines on the diagnosis and management of VWD, in collaboration with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH).
A 2019 collaboration with the American Society of Clinical Oncology (ASCO) to address the management of cancer-related anemia.
In 2023, in response to long-standing member interest, ASH approved a plan to develop clinical practice guidelines about aplastic anemia. Like other ASH guidelines, these new guidelines will be developed using methods that meet the highest standards for rigor and trust.
These guidelines will provide recommendations about alternative screening and diagnostic tests and testing strategies during the initial evaluation and workup of amyloidosis.